Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) is now available.
Hemogenyx Pharmaceuticals announced the automatic conversion of its convertible loan notes into 95,000 ordinary shares, with these shares set to be admitted to trading on the London Stock Exchange on 14 March 2025. This conversion increases the company’s total issued share capital to 3,699,539 ordinary shares, impacting shareholder calculations under the Disclosure Guidance and Transparency Rules.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a clinical stage biopharmaceutical company headquartered in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing distinct product candidates and platform technologies for novel product development.
YTD Price Performance: -53.89%
Average Trading Volume: 31,086
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £7.08M
For a thorough assessment of HEMO stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue